Benzinga

Benzinga

Benzinga

viernes, agosto 21

Palvella Therapeutics Inc

PVLANASDAQ
Trade with Public
Trade with Public
$145.50
2.922.05%
Últ. Act.: Aug 21, 9:16 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Palvella Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Palvella Therapeutics (PVLA).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

1S.Buy
15Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$161Upside to Avg. PT+10.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 21, 2026Stephens & Co.Sudan LoganathanMaintainedOverweight$220
May 21, 2026Chardan CapitalGeulah LivshitsMaintainedBuy$240
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.
Benzinga Newsdesk

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.
Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $255 to $270.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Palvella Therapeutics, Raises Price Target to $250

Mizuho analyst Graig Suvannavejh maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $205 to $250.
Benzinga Newsdesk

CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday

Avi Kapoor

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved